Aratana Therapeutics
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
$20.0m | Series A | ||
N/A | $15.0m | Series B | |
$12.0m | Series C | ||
N/A | N/A | IPO | |
N/A | $29.8m | Post IPO Equity | |
N/A | €50.0k | Grant | |
N/A | $40.0m | Post IPO Debt | |
N/A | $11.7m | Post IPO Equity | |
* | N/A | Acquisition | |
Total Funding | €42.8m |
Related Content
Recent News about Aratana Therapeutics
EditAratana Therapeutics, now part of Elanco, specializes in developing and commercializing innovative therapeutics for pets. The company focuses on providing solutions that improve the health and quality of life for companion animals, including dogs and cats. Aratana operates in the animal health market, serving veterinarians and pet owners who seek advanced treatments for their pets. The business model revolves around the research, development, and commercialization of veterinary pharmaceuticals, which are sold through veterinary clinics and pet hospitals. Revenue is generated primarily through the sale of these therapeutic products. Aratana's portfolio includes treatments for pain management, cancer, and other chronic conditions in pets. The company leverages its expertise in veterinary medicine to address unmet medical needs in the pet care industry.
Keywords: veterinary pharmaceuticals, pet therapeutics, animal health, pain management, cancer treatment, chronic conditions, pet care, veterinary clinics, pet hospitals, innovative solutions.